1:06 PM
Aug 01, 2018
 |  BC Innovations  |  Distillery Therapeutics


INDICATION: Lung cancer

Patient sample, cell culture and mouse studies suggest inhibiting activin signaling could enhance the efficacy of platinum-based chemotherapy in KRAS-mutant lung cancer. In 59 patients with stage IV non-small cell lung cancer (NSCLC) lacking activating mutations in EGFR or anaplastic lymphoma kinase (ALK) and receiving platinum-based chemotherapy, high tumor levels of three activin signaling components -- activin A, MSTN and GDF11 -- were associated with poor progression-free survival. In four KRAS-mutant human...

Read the full 347 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >